Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One World Trade Center, 22Nd Floor NEW YORK NY 10007 |
Tel: | N/A |
Website: | https://www.axsome.com |
IR: | See website |
Key People | ||
Herriot Tabuteau Chairman of the Board, President, Chief Executive Officer, Founder | Nick Pizzie Chief Financial Officer | Mark L. Jacobson Chief Operating Officer |
Lori Englebert Executive Vice President - Commercial and Business Development | Hunter Murdock General Counsel |
Business Overview |
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine. |
Financial Overview |
For the three months ended 31 March 2024, Axsome Therapeutics Inc revenues decreased 21% to $75M. Net loss increased from $11.2M to $68.4M. Revenues reflect License revenue decrease from $65.7M to $0K. Higher net loss reflects General and administrative - other increase of 40% to $58.8M (expense), Research and development - Other increase from $14.3M to $29.7M (expense), Stock-based Compensation in SGA increase of 48% to $15.6M (expense). |
Employees: | 545 as of Feb 13, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $3,503M as of Mar 31, 2024 |
Annual revenue (TTM): | $251.02M as of Mar 31, 2024 |
EBITDA (TTM): | -$285.72M as of Mar 31, 2024 |
Net annual income (TTM): | -$296.38M as of Mar 31, 2024 |
Free cash flow (TTM): | -$193.34M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 47,495,827 as of Apr 29, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |